Research Articles
68. Taṣ I., Jacobs R., Albrecht J., Barrientos S.A., Åberg J., Sime W., Brunnström H., Persson H., Kazi J.U. and Massoumi R. (2025) Advanced organoid models for targeting Kras -driven lung adenocarcinoma in drug discovery and combination therapy. Journal of Experimental & Clinical Cancer Research, 44: 128. (Pubmed)
67. Mousafi Alasal L., Hammarlund E.U., Pienta K.J., Rönnstrand L. and Kazi J.U. (2025) XeroGraph: enhancing data integrity in the presence of missing values with statistical and predictive analysis. Bioinformatics Advances, 5(1) vbaf035 (Pubmed).
66. Christensson G., Bocci M., Kazi J.U., Durand G., Lanzing G., Pietras K. Velozo H.G., and Hagerling C. (2024) Spatial multiomics reveal intratumoral immune heterogeneity with distinct cytokine networks in lung cancer brain metastases. Cancer Research Communications, 4(11):2888-2902 (Pubmed).
65. Manaprasertsaka A., Kazi J.U., Hagerling C., Pienta K.J., Malmbergd P., and Hammarlund E.U. (2024) Alterations of the chemical profile of cholesterol in cancer tissue as traced with ToF-SIMS. Analyst, 149(21):5344-5352 (Pubmed).
64. Daams R., Tran P., Jemaà M, Sime W., Mickeviciute R. Ek S., Rönnstrand L., Kazi J.U., and Massoumi R. (2024) Enhancing cell death in B-cell malignancies through targeted inhibition of Bcl-3. Cell Death & Disease, 15(1) 690 (Pubmed).
63. Younus S., Rönnstrand L., and Kazi J.U. (2024) Xputer: Bridging Data Gaps with NMF, XGBoost, and a Streamlined GUI Experience. Frontiers in Artificial Intelligence 7(1) 1345179 (Pubmed).
62. Nasimian A., Younus S., Tatli Ö., Hammarlund E.U., Pienta K.J., Rönnstrand L., and Kazi J.U. (2024) AlphaML: A clear, legible, explainable, transparent, and elucidative binary classification platform for Tabular data. Patterns 5(1) 100897 (Pubmed).
61. Saamarthy K., Ahlqvist K., Daams R., Balagunaseelan N., Rinaldo-Matthis A., Kazi J.U., Sime W. and Massoumi R. (2024) Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells. BMC Cancer 24(1) 102 (Pubmed).
60. Liu A, Zhang S, Wang M, Zhang L, Xu S, Nasimian A, Li S, Zhao S, Cao X, Tian J, Yu Y, Fan Z, Xiao K, Zhao H, Kazi J.U., Ma L, and Sun J. (2024) DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors. Molecular Carcinogenesis 63(1):75-93 (Pubmed).
59. Tari K., Nasimian A., Kazi J.U. and Abroun S. (2023) Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of BCL-2. International Journal of Molecular and Cellular Medicine 12(3) (Link).
58. Kazi J.U., Al Ashiri, L., Purohit R. and Rönnstrand L. (2023) Understanding the role of activation loop mutants in drug efficacy for FLT3-ITD. Cancers 15(22): 5426 (Pubmed).
57. Shah K., Nasimian A., Ahmed M., Al Ashiri L., Denison L., Sime W., Bendak K., Kolosenko I., Siino V., Levander F., Palm-Apergi C., Massoumi R., Lock R.B., and Kazi J. U. (2023) PLK1 as a Cooperating Partner for BCL2-Mediated Antiapoptotic Program in Leukemia. Blood Cancer Journal 13:139 (Pubmed).
56. Shah K., Al Ashiri L., Nasimian A., Ahmed M., Kazi J. U. (2023) Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling. International Journal of Molecular Sciences 24(5): 5004 (Pubmed, Link, Lund University).
55. Nasimian A., Al Ashiri L., Ahmed M., Daun H., Zhang X., Rönnstrand L., Kazi J. U. (2023) A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia. International Journal of Molecular Sciences 24(4): 3830 (Pubmed, Link, Lund University).
54. Nasimian A., Ahmed M., Hedenfalk I., Kazi J. U. (2023) A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer. Computational and Structural Biotechnology Journal 21: 956-964 (Pubmed, Link, Lund University,).
53. Emdal K. B., Palacio-Escat N., Wigerup C., Eguchi A., Nilsson H., Bekker-Jensen D. B., Rönnstrand L., Kazi J. U., Puissant A., Itzykson R., Saez-Rodriguez J., Masson K-, Blume-Jensen P., Olsen J. V. (2022) Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance. Cell Report 40(6):111177 (Pubmed, Link, Lund University).
52. Shah K, Ahmed M and Kazi J. U. (2021) The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia. npj Precision Oncology 5(1):13 (Pubmed, Link, Lund University, ResearchGate).
51. Nordgaard C, Doll S, Matos A. L, Høeberg M, Kazi J. U., Friis S., Stenvang J., Rönnstrand L., Mann M., and Moreira J. M. (2019) Metallopeptidase Inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer. Molecular Oncology 13(12):2646-2662 (Pubmed, Link, Lund University, ResearchGate).
50. Chougule R. A., Shah K., Moharram S. A., Vallon-Christersson J. and Kazi J. U. (2019) Glucocorticoid-resistant B-cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation. npj Genomic Medicine 4:7 (Pubmed, Link, Lund University, ResearchGate).
49. Moharram S. A., Shah K., Khanum F., Rönnstrand L. and Kazi J. U. (2019) The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood Cancer Journal 9:5 (Pubmed, Link, Lund University, ResearchGate).
48. Li T., Deng Y., Shi Y., Tian R., Chen Y., Zou L., Kazi J. U., Rönnstrand L., Feng B., Chan S. O., Chan W. Y., Sun J., and Zhao H. (2018) Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene 37(47): 6180-6194 (Pubmed, Link, Lund University, ResearchGate).
47. Shah K., Moharram S. A. and Kazi J. U. (2018) Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression. Clinical Epigenetics 10:83 (Pubmed, Link, Lund University, ResearchGate).
46. Hyrenius-Wittsten A., Pilheden M., Sturesson H., Hansson J., Walsh M. P., Song G., Kazi J. U., Liu J., Ramakrishan R., Garcia-Ruiz C., Nance S., Gupta P., Zhang J., Rönnstrand L., Hultquist A., Downing J. R., Lindkvist-Petersson K., Paulsson K., Järås M., Gruber T. A., Ma J., and Andersson-Hagström A. K. (2018) De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. Nature Communications 9(1): 1770 (Pubmed, Link, Lund University, ResearchGate).
45. Rupar K., Moharram S. A., Kazi J. U. and Rönnstrand L. (2018) Src-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation. Scientific Reports 8(1): 6405 (Pubmed, Link, Lund University, ResearchGate).
44. Moharram S. A., Shah K. and Kazi J. U. (2017) T-cell acute lymphoblastic leukemia cells display activation of different survival pathways. Journal of Cancer 8(19): 4124-4129 (Pubmed, Link, Lund University, ResearchGate).
43. Marhäll A., Kazi J. U. and Rönnstrand L. (2017) The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation. Scientific Reports 7(1): 13734 (Pubmed, Link, Lund University, ResearchGate).
42. Moharram S. A., Shah K., Khanum F., Marhäll A., Gazi M. and Kazi J. U. (2017) Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia. Cancer Letters 405(1): 73-78 (Pubmed, Link, Lund University, ResearchGate).
41. Phung B., Kazi J. U., Lundby A., Bergsteinsdottir K., Sun J., Goding C. R., Jönsson G., Olsen J. V., Steingrimsson E., and Rönnstrand L. (2017) KITD816V induces SRC-mediated tyrosine phosphorylation of MITF and altered transcription program in melanoma. Molecular Cancer Research 15(9): 1265-1274 (Pubmed, Link, Lund University, ResearchGate).
40. Kazi J. U., Chougule R. A., Li T., Su X., Moharram S. A., Rupar K., Marhäll A., Gazi M., Sun J., Zhao H. and Rönnstrand L. (2017) Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD. Cellular and Molecular Life Sciences 74(14): 2679–2688 (Pubmed, Link, Lund University, ResearchGate).
39. Gazi M., Moharram S. A., Marhäll A. and Kazi J. U. (2017) The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). Cancer Letters 392(1): 9-16 (Pubmed, Link, Lund University, ResearchGate).
38. Kazi J. U., Rupar K., Marhäll A., Moharram S. A., Khanum F., Shah K., Gazi M., Nagaraj S. R., Sun J., Chougule R. A. and Rönnstrand L. (2017) ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling. Oncotarget 8(7): 12194-12202 (Pubmed, Link, Lund University, ResearchGate).
37. Moharram S. A., Chougule R. A., Su X., Li T., Sun J., Zhao H., Rönnstrand L. and Kazi J. U. (2016) Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling. Oncotarget 7(36): 57770-82 (Pubmed, Link, Lund University, ResearchGate).
36. Lindblad O., Cordero E., Puissant A., Macaulay L., Ramos A., Kabir N. N., Sun J., Vallon-Christersson J., Haraldsson K., Hemann M. T., Borg Å, Levander F., Stegmaier K., Pietras K., Rönnstrand L. and Kazi J. U. (2016) Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene 35(39): 5119-31 (Pubmed, Link, Lund University, ResearchGate).
35. Chougule R. A., Cordero E., Moharram S. A., Pietras K., Rönnstrand L. and Kazi J. U. (2016) Expression of GADS enhances FLT3-induced mitogenic signaling. Oncotarget 7(12): 14112-24 (Pubmed, Link, Lund University, ResearchGate).
34. Alam M. W., Persson C. U., Reinbothe S., Kazi J. U., Rönnstrand L., Wigerup C., Ditzel H. J., Lykkesfeldt A. E., Påhlman S. and Jögi A. (2016) HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells. Oncotarget 7(10): 11238-50 (Pubmed, Link, Lund University, ResearchGate).
33. Chougule R. A., Kazi J. U. and Rönnstrand L. (2016) FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia. Oncotarget 7(9): 9964-74 (Pubmed, Link, Lund University, ResearchGate).
32. Lindblad O., Chougule R. A., Moharram S. A., Kabir N. N., Sun J., Kazi J. U. and Rönnstrand L. (2015) The role of HOXB2 and HOXB3 in acute myeloid leukemia. Biochemical and Biophysical Research Communications 467(4): 742-747 (Pubmed, Link, Lund University, ResearchGate).
31. Zhang J., Vakhrusheva O., Bandi S. R., Demirel Ö., Kazi J. U., Fernandes R. G., Jakobi K., Eichler A., Rönnstrand L., Carpino N., Serve H. and Brandts C. H. (2015) The phosphatases STS1 and STS2 regulate hematopoietic stem and progenitor cell fitness. Stem Cell Reports 5(4): 633-646 (Pubmed, Link, Lund University, ResearchGate).
30. Lindblad O., Kazi J. U., Rönnstrand L. and Sun J. (2015) PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase independent manner. Cellular and Molecular Life Sciences 72(22): 4399-4407 (Pubmed, Link, Lund University,ResearchGate).
29. Lindblad O., Li T., Su X., Sun J., Kabir N. N., Levander F., Zhao F., Lu G., Rönnstrand L. and Kazi J. U. (2015) BEX1 acts as a tumor suppressor in acute myeloid leukemia. Oncotarget 6(25): 21395-21405 (PubMed, Link, Lund University, ResearchGate).
28. Agarwal S., Kazi J. U., Mohlin S., Påhlman S., and Rönnstrand L. (2015) The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V. Oncogene, 34(35): 4581-4590 (PubMed, Link, Lund University, ResearchGate).
27. Sun J., Mohlin S., Lundby A., Kazi J. U., Hellman U., Påhlman S., Olsen J. V. and Rönnstrand L. (2014) The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase independent manner. Oncogene 33(46): 5360-5369 (Pubmed, Link, Lund University, ResearchGate).
26. Kabir N. N., Rönnstrand L. and Kazi J. U. (2014) Keratin 19 expression correlates with poor prognosis in breast cancer. Molecular Biology Reports 41(12): 7729-7735 (Pubmed, Link, Lund University, ResearchGate).
25. Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil C.F., Mehta S, Du J, Kazi J. U., Luciano F, Rönnstrand L, Kung A. L., Aster J. C., Galinsky I., Stone R. M., DeAngelo D. J., Hemann M. T. and Stegmaier K (2014) SYK Is a Critical Regulator of FLT3 In Acute Myeloid Leukemia. Cancer Cell 25(2): 226-242 (Pubmed, Link, Lund University, ResearchGate, Comment, Comment, Comment).
24. Kazi J. U., Agarwal S., Sun J., Bracco E. and Rönnstrand L. (2014) Src-Like Adaptor Protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling. Journal of Cell Science 127 (3): 653-662 (Pubmed, Link, Lund University, ResearchGate).
23. Agarwal S., Kazi J. U. and Rönnstrand L. (2013) Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation. Journal of Biological Chemistry 288 (31): 22460-22468 (Pubmed, Link, Lund University, ResearchGate).
22. Kabir N. N., Rönnstrand L. and Kazi J. U. (2013) Protein Kinase C expression is deregulated in chronic lymphocytic leukemia. Leukemia and Lymphoma 54(10): 2288-2290. ( Pubmed, Link, Lund University, ResearchGate, Commentary).
21. Kazi J. U., Vaapil M., Agarwal S., Bracco E., Påhlman S. and Rönnstrand L. (2013) The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cellular Signalling 25(9): 1852-1860 (Pubmed, Link, Lund University, ResearchGate).
20. Kabir N. N., Rönnstrand L. and Kazi J. U. (2013) The basic helix-loop-helix (bHLH) proteins in breast cancer progression. Medical Oncology 30(3): 666 (Pubmed, Link, Lund University, ResearchGate).
19. Kabir N. N., Rönnstrand L. and Kazi J. U. (2013) Deregulation of protein phosphatase expression in acute myeloid leukemia. Medical Oncology 30(2): 517 (Pubmed, Link, Lund University, ReaearchGate).
18. Kazi J. U., Sun J. and Rönnstrand L. (2013) The presence or absence of IL-3 during long-term culture of Flt3-ITD and c-Kit-D816V expressing Ba/F3 cells influences signaling outcome. Experimental Hematology 41(7): 585-587 (Pubmed, Link, Lund University, ResearchGate).
17. Kazi J. U. and Rönnstrand L. (2013) Suppressor of Cytokine Signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Molecular Oncology 7(3): 693-703 (Pubmed, Link, Lund University, ResearchGate).
16. Kabir N. N., Rönnstrand L. and Kazi J. U. (2013) FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL). Medical Oncology 30(1):462 (Pubmed, Link, Lund University, ResearchGate).
15. Kazi J. U. and Rönnstrand L. (2013) FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. Molecular Oncology 7(3): 402-418 (Pubmed, Link, Lund University, ResearchGate).
14. Kabir N. N. and Kazi J. U. (2013) Selective mutation in ATP-binding site reduces affinity of drug to the kinase: a possible mechanism of chemo-resistance. Medical Oncology 30(1): 448 (Pubmed, Link, Lund University, ResearchGate).
13. Kazi J. U. and Rönnstrand L. (2012) Src-like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling. PLoS One 7(12): e53509 (Pubmed, Link, Lund University, ResearchGate).
12. Kazi J. U., Sun J., Phung B., Zadjali F., Flores-Morales A. and Rönnstrand L. (2012) Suppressor of Cytokine Signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated Tyr 591 and Tyr 919 of Flt3. Journal of Biological Chemistry287(43): 36509-36517 (Pubmed, Link, Lund University, ResearchGate).
11. Lin D. C., Yin T., Koren-Michowitz M., Ding L. W., Gueller S., Gery S., Tabayashi T., Bergholz U., Kazi J. U., Rönnstrand L., Stocking C. and Koeffler H. P. (2012) Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. Blood 120(16): 3310-3317 (Pubmed, Link, Lund University, ResearchGate).
10. Kabir N. N., Hossain M. I. and Kazi J. U. (2011) Comparative Studies on Human and Rat Basic Helix-loop-helix Proteins. Asian Journal of Biological Sciences 4(8): 601-608 (Link, Lund University, ResearchGate).
9. Khan M. M. G., Rydén A. M., Chowdhury M. S., Hasan M. A. and Kazi J. U. (2011) Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites. Gene 483(1-2): 29-35 (Pubmed, Link, Lund University, ResearchGate).
8. Kabir N. N. and Kazi J. U. (2011) Comparative analysis of human and bovine protein kinases reveals unique relationship and functional diversity. Genetics and Molecular Biology 34(4): 587-591 (Pubmed, Link, Lund University, ResearchGate).
7. Kim H. J., Kazi J. U., Lee Y. R., Nguyen D. H., Lee H. B., Shin J. H., Soh J. W., Kim E. K. (2010) Visualization of the melanosome transfer-inhibition in a mouse epidermal cell co-culture model. International Journal of Molecular Medicine 25(2): 249-253 (Pubmed, Link, Lund University, ResearcgGate).
6. Kazi J. U., Kim C.R. and Soh J. W. (2009) Subcellular localization of diacylglycerol-responsive protein kinase C isoforms in HeLa cells. Bulletin of the Korean Chemical Society 30(9): 1981-1984 (Link, Lund University, ResearchGate).
5. Kazi J. U. and Soh J. W. (2008) Induction of the Nuclear Proto-Oncogene c-fos by the Phorbol Ester TPA and c-H-Ras. Molecules and Cells 26(5): 462-467 (Pubmed, Link, Lund University, ResearchGate).
4. Soh J. W., Kazi J. U., Li H., Thompson W. J. and Weinstein I. B. (2008) Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Molecular Carcinogenesis 47(7): 519-525 (Pubmed, Link, Lund University, ResearchGate).
3. Kazi J. U. and Soh J. W. (2008) Role of regulatory domain mutants of PKC isoforms in c-fos induction. Bulletin of the Korean Chemical Society 29(1): 252-254 (Link, Lund University, ResearchGate).
2. Kazi J. U., Kabir N. N. and Soh J. W. (2008) Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. Gene410(1): 147-153 (Pubmed, Link, Lund University, ResearchGate).
1. Kazi J. U. and Soh J. W. (2007) Isoform-specific translocation of PKC isoforms in NIH3T3 cells by TPA. Biochemical and Biophysical Research Communications 364(2): 231-237 (Pubmed, Link, Lund University, ResearchGate).